Industry
LYPHE Group launches industry-first patient representative board
The board aims to ensure that patient’s voices are heard in the industry.
In an industry first, LYPHE is bringing patients to the table to explore how to improve the patient experience across the organisation – and the wider industry.
Registration is now open for the company’s newly created Patient Representative Board, which will focus on patient concerns and issues in the medical cannabis industry.
It will be formed of independent patients from across the UK, Channel Islands and Isle of Man, as well as representatives from patient groups and charities.
Since the rescheduling of medical cannabis in November 2018, LYPHE has been a key player in patient access, with the large majority of patients using its clinical services and dispensary to obtain medication.
The teething pain and successes of the global medical cannabis industry have been well documented by commentators and patients alike.
Announcing the news, LYPHE said the industry’s first Patient Representative Board would ensure patient voices are heard.
Meetings will be held monthly, and feedback from the sessions will be used to further explore how to improve the patient experience.
By working together, LYPHE hopes to bring about changes that will benefit the wider patient community, as well as shape the organisation’s future direction.
Discussing the initiative, LYPHE Group Managing Director Jonathan Nadler, said: “I’m delighted LYPHE is taking the initiative in working closely with patients. We want to build a stronger, more sustainable industry whilst continuing our journey for full patient access.
“The issues that impact our business, and the medical cannabis industry, ultimately impact our patients, which is why improving transparency with patient groups is vital.”
For more information on how to apply visit www.lyphegroup.com.featured
Applicants or patient groups can register their interest by emailing their details along with reasons why they would like to join the Board via the contact form.
Membership will be limited to a total of 12 representatives in addition to the two chairs.
-
Health3 months agoCannabis linked to ‘substantial improvements’ in endometriosis symptoms
-
News4 months agoGrounding of British Airways flight sparks calls for more medical cannabis education
-
Industry4 months agoThe tipping point? UK cannabis clinics urged to clean up ‘concerning’ prescribing practices
-
Industry6 months agoLyphe UK to Launch Noidecs Vital, a New Low-Cost Medical Cannabis Line
-
News5 months agoA new centre-left government and the potential for ‘change’ in the UK cannabis landscape
-
Health6 months agoNew UK study highlights scale of illegal cannabis use for health reasons
-
Science5 months agoCBG found to reduce anxiety and enhance memory in clinical trial
-
Epilepsy2 months ago
UCL Launches 2 Medical Cannabis Trials Into Childhood Epilepsy, but Experts Warn It Is Not the Solution Many Have Been Waiting For
